Aura Biosciences, Inc. — Director's Dealing 2021

Oct 28, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aura Biosciences, Inc. (AURA)
CIK: 0001501796
Period of Report: 2021-10-28

Reporting Person: Matrix Capital Management Company, LP (10% Owner)
Reporting Person: GOEL DAVID E. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series E Convertible Preferred Stock	$		Common Stock, par value $0.00001 per share (2327870)		Indirect

Footnotes

F1: The Series E Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date. The shares of Series E Convertible Preferred Stock will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.

F2: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.